BLOCKCHAIN BIOPHARMA: INVESTMENT GOALS AND CRITERIA DATA

Investment will go toward software development, #Data Collection operations, digital advertising, regulatory and compliance for a global scale, liquidity, and market maker services.

Currently, we are working to integrate 26 different global derivative and cryptocurrency trading platforms to list our Pharmaceutical Token (Ticker: PHARMA)

We have selected #Consensys's MetaMask Institutional Account, and several other high-security / high-quality Crypto Wallets to safely store Pharmaceutical Tokens (Ticker: PHARMA), including cold-storage.

• TIME-FRAME

  • 3-Months

• MINIMUM NEEDED FOR COMMERCIAL VIABILITY

  • $25 Million

• MAXIMUM NEEDED FOR CROWD FUNDING SERIES A, B, C

  • $300 Million

• $25 MM Seed Round

  • Investors will be granted voting rights in the DAO, powered by transparent Voting Smart Contracts. Collaboration in this early stage is critical, and we seek partners with a vested interest in the success of Blockchain BioPharma's #Mission. We want only high performers.

• MINIMUM TOKEN PRICING FOR ENTERPRISES:

  • $6.00 - 1 Million PHARMA Tokens Purchased

  • $5.00 - 2 Million PHARMA Tokens Purchased

  • $4.00 - 3 Million PHARMA Tokens Purchased

• CASH FLOW REQUIREMENTS WITH $20(M) INVESTMENT MINIMUM

  • [$500(k)] = Monthly Startup Burn Data (Platform Development, Advertising / Partnership Development, Survey, Research & Development, and Scrum Team)

  • [$250(k)] = Remaining Regulatory Licensing Costs

  • [$100,000(k)] = Approximate 3rd - Party Data Providers

  • [$50(k) = Auditing and Remittal of Audits via #Regulatory and #Compliance Smart Contracts $100,000

Software Products & Services

WE DO NOT MAKE INVESTMENT RETURN PROMISES THUS NO PRO-FORMAS. WE ONLY PRESENT EXISTING QUALITATIVE AND QUANTITAVE DATA AVAILABLE

CRYPTO IS A RISKY BUSINESS – LASTLY, VOTERS IN OUR DECENTRALIZED AUTONOMOUS ORGANIZATION WILL INFORM THE BUSINESS, eNFT INVESTMENT, AND MANAGEMENT DECISIONS - TARGET DATE Q2 2022.

REQUIRED READING:

The US Treasure Departments Stablecoin Analysis

o Investor Relations Contact: [e-mail]